Holen Sie sich die Stockscreener-App
0.171
6.28%
0.0101
Handel nachbörslich:
.17
-0.001
-0.58%
Schlusskurs vom Vortag:
$0.1609
Offen:
$0.157
24-Stunden-Volumen:
3.35M
Relative Volume:
3.85
Marktkapitalisierung:
$2.29M
Einnahmen:
$142.00K
Nettoeinkommen (Verlust:
$-1.23M
KGV:
0.3672
EPS:
0.4657
Netto-Cashflow:
$-10.62M
1W Leistung:
-3.50%
1M Leistung:
-37.25%
6M Leistung:
-88.68%
1J Leistung:
-94.04%
1-Tages-Spanne:
$0.1495
$0.19
1-Wochen-Bereich:
$0.1495
$0.19
52-Wochen-Spanne:
$0.1495
$3.40
Vivosim Labs Inc Stock (VIVS) Company Profile
Firmenname
Vivosim Labs Inc
Sektor
Branche
Telefon
858-224-1000
Adresse
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
0.171 | 2.29M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-12-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-11-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | Eingeleitet | Raymond James | Outperform |
| 2015-08-11 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | Eingeleitet | Jefferies | Buy |
| 2015-06-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Vivosim Labs Inc Aktie (VIVS) Neueste Nachrichten
Press Releases about Volato Group, Inc. Class A Common Stock (NYSE:SOAR) - FinancialContent
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials - Carroll County Mirror-Democrat
Received 5M from Eli Lilly - Moomoo
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - openPR.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - WBOC TV
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - marketscreener.com
VivoSim Labs (VIVS) CCO buys 10,000 shares outside trading plan - Stock Titan
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - FinancialContent
VivoSim plans rat liver model to complement human testing - Investing.com
VivoSim Labs to Add Rat Liver Model to NAMkind Platform - Yahoo Finance UK
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - Barchart.com
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent
Big Pharma giant Eli Lilly pays $6M to VivoSim Labs 🤯🔥 $Xiao-I (AIXI.US)$ $CID Holdco (DAIC.US)$ - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - openPR.com
VivoSim Labs (VIVS) News Flow - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
The Largest Pharma On The Planet Sent Cash to a Micro cap 👀 - Moomoo
VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency - TipRanks
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VivoSim Labs, INC. SEC Filing (Aug 21, 2026) - Stock Titan
Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10% - Stock Titan
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - WBOC TV
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - FinancialContent
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as - openPR.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus - FinancialContent
VivoSim Labs (VIVS) seeks approval for reverse split, equity plan and warrant repricing - Stock Titan
VivoSim: Fiscal Q1 Earnings Snapshot - marketscreener.com
VivoSim: Fiscal Q1 Earnings Snapshot - KTVB
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside - FinancialContent
$VIVS Load up 🔥🚀 - Moomoo
VivoSim Labs, INC. SEC Filing (Aug 11, 2026) - Stock Titan
VivoSim Labs (NASDAQ: VIVS) seeks approval for reverse split, warrant share issuance - Stock Titan
VivoSim Labs (VIVS) Revenue BreakdownMain Composition - Moomoo
VivoSim Labs (VIVS) News Flow - Moomoo
VIVS PE Ratio & Valuation, Is VIVS Overvalued - Intellectia AI
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Moomoo
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com UK
VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 - Minichart
VivoSim Labs regains Nasdaq compliance after cash infusion - Investing.com
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com Nigeria
🍋💦🍋💦💣🚀 - Moomoo
VivoSim Provides Financial and Listing Compliance Update - The Manila Times
VivoSim regains Nasdaq compliance after $10.1 million cash update - Quiver Quantitative
Finanzdaten der Vivosim Labs Inc-Aktie (VIVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):